Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites

Liver International

Volumn 33, Issue 9, 2013, Pages 1316-1323

  de Vos, Marie ^a   De Vroey, Bénédicte ^a   Garcia, Béatrice Garcia ^a   Roy, Clothilde ^a   Kidd, François ^a   Henrion, Jean ^a   Deltenre, Pierre ^a,b  

^a Hospital de Jolimont   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Ascites; Cirrhosis; Proton pump inhibitors; Spontaneous bacterial peritonitis; Survival

Indexed keywords

ANTIBIOTIC AGENT; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETROSPECTIVE STUDY;

ASCITES; CIRRHOSIS; PROTON PUMP INHIBITORS; SPONTANEOUS BACTERIAL PERITONITIS; SURVIVAL;

ASCITES; BACTERIAL TRANSLOCATION; CASE-CONTROL STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; PERITONITIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84883810972     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12210     Document Type: Article

References (53)

1. Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37: 897-901.
2. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32: 142-53.
3. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-8.
4. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
5. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
6. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
7. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-56, 1256.e1-5.
8. Garcia-Tsao G. Bacterial translocation: cause or consequence of decompensation in cirrhosis? J Hepatol 2001; 34: 150-5.
9. Llovet JM, Bartoli R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol 1998; 28: 307-13.
10. Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39: 484-91.
11. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44: 633-9.
12. Campillo B, Pernet P, Bories PN, et al. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-9.
13. Casafont Morencos F, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996;41:552-6.
14. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl 1): S1-12.
15. Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci 1997; 42: 738-42.
16. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43-8.
17. Ramachandran A, Balasubramanian KA. Intestinal dysfunction in liver cirrhosis: its role in spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2001; 16: 607-12.
18. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139: 186-93.
19. Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 2012; 61: 1219-25.
20. Kalaitzakis E, Bjornsson E. Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2008; 20: 512-8.
21. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-38.
22. Rabinovitz M, Yoo YK, Schade RR, et al. Prevalence of endoscopic findings in 510 consecutive individuals with cirrhosis evaluated prospectively. Dig Dis Sci 1990; 35: 705-10.
23. Shaheen NJ, Stuart E, Schmitz SM, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005; 41: 588-94.
24. Lodato F, Azzaroli F, Di Girolamo M, et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol 2008; 14: 2980-5.
25. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 2962-7.
26. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-9.
27. van Vlerken LG, Huisman EJ, van Hoek B, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest 2012; 42: 760-7.
28. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10: 557-61.
29. Parkman HP, Urbain JL, Knight LC, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998; 42: 243-50.
30. Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000; 22: 357-72.
31. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000; 14(Suppl 1): 74-81.
32. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118-22.
33. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
34. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418-23.
35. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-90.
36. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-60.
37. Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994; 120: 653-62.
38. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104: 1130-4.
39. Bulsiewicz WJ, Scherer JR, Feinglass JM, Howden CW, Flamm SL. Proton pump inhibitor (PPI) use is independently associated with spontaneous bacterial peritonitis (SBP) in cirrhotics with ascites. Gastroenterology 2009; 136: A11.
40. Choi EJ, Lee HJ, Kim KO, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011; 46: 616-20.
41. Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10: 422-7.
42. Northup PG, Argo CK, Berg CL. Chronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patients. Hepatology 2008; 48: 325A.
43. Ratelle M, Beaudoin A, Perreault S, Villeneuve J, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 2012; 142: A104.
44. Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008; 53: 394-8.
45. Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
46. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91, 1391.e1-5.
47. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011; 140: 1084-91.
48. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107: 345-60; quiz 361.
49. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
50. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374: 1449-61.
51. Liver EAftSot. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
52. Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009; 104: 993-1001; quiz 1002.
53. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-33.